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Introduction:  The  growing  number  of  long-term  cancer  survivors  poses  a new  challenge  to health  care
systems.  In Spain,  follow-up  is  usually  carried  out in oncology  services,  but knowledge  of  cancer  survivors’
health care  needs  in this  context  is  limited.  The  purpose  of  this  study  was  to  ascertain  the  health  status
of  long-term  survivors  of breast,  prostate,  and  colorectal  cancer  and  to  characterize  their  use  of health
care  services.
Methods:  Retrospective  multicenter  cohort  study.  We  collected  data  from  patients’  clinical  histories  and
through telephone  interviews,  using  a specially  designed  questionnaire  that  included  the SF-36v2 Quality
of Life  and Nottingham  Health  Proﬁle  scales.
Results: The  questionnaire  was  completed  by 51.2%  (n=  583)  of the potential  sample.  No  signiﬁcant
differences  were  observed  between  5-year  and  10-year  survivors.  Overall,  more  than  80%  of respondents
were  undergoing  drug  treatment  for  morbidity  related  to advanced  age.  Quality  of life  was  good  in  most
patients,  and  cancer-related  morbidity  was  low  and  of  little  complexity.  For  the  most  part,  participants
reported  using  primary  care  services  for care  of chronic  diseases  and  opportunistic  treatment  of  sequelae
related  to the  cancer  treatment.  Oncological  follow-up  was  centralized  at the  hospital.
Conclusions:  Survivors  of  breast,  prostate  and  colorectal  cancer  with  tumoral  detection  at  an  early  stage
and  without  recurrences  or second  neoplasms  experienced  little  morbidity  and  enjoyed  good  quality  of
life. This  study  proposes  exploration  of  a  follow-up  model  in  the  Spanish  health  system  in which  primary
care  plays  a more  important  role than  is  customary  in  cancer  survivors  in  Spain.
© 2013  SESPAS.  Published  by Elsevier  España,  S.L.  All rights  reserved.
Estado  de  salud  y  uso  de  recursos  sanitarios  en  largos  supervivientes  de  cáncer
de  mama,  colorectal  y  próstata
alabras clave:
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Introducción:  El creciente  número  de supervivientes  de  larga  evolución  de  cáncer  es  un  nuevo  reto  para  los
sistemas  sanitarios.  En  Espan˜a,  su seguimiento  se desarrolla  principalmente  en  los  servicios  oncológicos
y  el conocimiento  actual  sobre  sus necesidades  sanitarias  es en  este  contexto  limitado.  El  objetivo  de este
estudio  es conocer  el estado  de  salud  de  los supervivientes  de  larga  evolución  en  los  tumores  de  mama,
próstata  y  colorrectal  y caracterizar  el uso  de  los  recursos  sanitarios  que  éstos  realizan.
Métodos:  Estudio  multicéntrico  de  cohortes  retrospectivo.  Se  recogió  la  información  de  la  historia  clínica
y de  entrevista  telefónica  a los  pacientes  mediante  un  cuestionario  especíﬁco  que  incluyó  los de  calidad
de  vida  SF-36v2  y  Perﬁl  de  Salud  de Nottingham.
Resultados:  Respondieron  el  51.2%  (583)  de la  muestra  potencial.  No  se  observaron  diferencias  signi-
ﬁcativas  entre  los supervivientes  entre  5  y  10  an˜os.  En  conjunto,  más  del 80%  seguían  tratamiento
farmacológico  debido  a la morbilidad  relacionada  con  la  edad  avanzada.  La  mayoría  tenía  buena  calidad
de vida  y la  morbilidad  asociada  al  cáncer  fue  reducida  y de  baja complejidad.  Mayoritariamente  frecuen-
tan  atención  primaria  para  las  patologías  crónicas  y  de  forma  oportunista  para las secuelas  relacionadas
cer.  El seguimiento  oncológico  está  centralizado  en  el  hospital.con  el tratamiento  de  cán
Conclusiones:  Los supervivientes  de cáncer  de  mama,  próstata  y colorrectal  diagnosticados  en  estadios
tempranos,  que  no  han  tenido  recurrencia  ni segundas  neoplasias,  presentan  limitada  morbilidad  y
∗ Corresponding author.
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tienen  buena  calidad  de  vida.  Este  estudio  propone  explorar  en  nuestro  sistema  sanitario  un modelo  de
seguimiento  donde  la atención  primaria  tenga  un rol más  relevante  que  el  actual  para  la  atención  de  los
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The recent increase seen in cancer survivorship among adults,
articularly for those with high-frequency tumors, renders it nec-
ssary to analyze these patients’ situations several years after
iagnosis in order to assess the adequacy of the health care pro-
ided for them. In the last decade, reported 5-year survival rates
or all cancers have reached 47.3% in men  and 55.8% in women in
urope,1 and in Spain, survival of breast, colorectal and prostate
ancer, all of them among the most frequent tumors, has been
stimated at 86%, over 50%, and 71.4%, respectively.2 Along with
he continuous rise in incidence, the growing number of survivors
oses a new challenge to health care systems3 due to the magni-
ude of the impact on health care services that these represent and
he still scant evidence available4,5 on the type of clinical follow-up
nd their health care needs.6 In this context, a variety of health care
odels and experiences have emerged, including those in which
rimary care participation predominates.7,8 Though these have dis-
layed viability from a clinical standpoint, scientiﬁc evidence is still
oo insufﬁcient to segment patient risk vis-à-vis treatment received
nd the appearance of long-term adverse effects.9
In Spain, the speciﬁc needs of long-term survivors have not yet
een documented. Accordingly, the main aim of this study was
o ascertain and compare the health status between the breast,
rostate and colorectal cancer survivors at 5 and 10 years, given
he high survival especially in breast tumor, and to characterize
heir use of health care services in order to generate knowledge
hat informs decision-making related to health care planning and
ollow-up for this population.
ethods
We  conducted a retrospective, cohort, multicenter study on
dult patients who were diagnosed with breast, colorectal and
rostate cancer in 2004 and 1999. The study was undertaken
n 2010 at four university tertiary hospitals: the Clinic Hospital,
he Parc Sanitari Mar  Hospital, the Bellvitge Hospital-Catalonian
nstitute of Oncology (L’Hospitalet) and the Germans Trias i Pujol
ospital-Catalonian Institute of Oncology (Badalona). The Clinical
esearch Ethics Committees in each health center approved the
tudy.
The study population was identiﬁed through analysis of the Cat-
lonian Hospital Discharge Minimum Basic Data Set (HDMBD) at
ach hospital and use of the International Classiﬁcation of Diseases-
th Revision (ICD-9). It included all patients diagnosed with breast,
olorectal and prostate cancer for the years 2004 and 1999 who
nderwent the complete treatment (surgery, chemotherapy, radio-
herapy, alone or in combination) at the same health center and
ave written, informed consent. Patients were excluded if they had
xperienced a recurrence, presented another primary neoplasm, or
ad died.
We  drew up a purpose-designed form divided into two sec-
ions: C1, to record clinical data obtained from a review of
linical histories, including tumor stage at diagnosis, treatment
nd adverse effects; and C2, to record data furnished directly
y the patients themselves via telephone interview. In this sec-
ion, the SF-36v2 Health-Related Quality of Life and Nottingham
ealth Proﬁle (NHP) Questionnaires were used to measure the
uality of life. The SF-36v2 incorporates two composite scales,
he physical component and the mental component scale, derivedpan˜a.
ESPAS.  Publicado  por Elsevier  España,  S.L. Todos  los  derechos  reservados.
from eight domains: physical functioning, role limitations due to
physical health problems, bodily pain, general health perception,
vitality, social functioning, role limitations due to emotional prob-
lems and general mental health. The higher scores indicating better
functioning.10 The NHP contains 6 categories: physical mobility,
pain, sleep, energy, social isolation and emotional reactions, where
the higher score the greater the health problem.11
Speciﬁc questions (similar to those used in the Catalonian Health
Survey12) were included to evaluate use of and satisfaction with
health care resources, while others dealt with life changes, com-
plementary therapies, use of medication and sociodemographic
aspects. The form was structured by close-ended questions and val-
idated in a sample of 30 patients drawn from all four hospitals. The
average length of interview was 25 minutes.
Cases were selected by applying the inclusion criteria to the clin-
ical histories of all diagnoses identiﬁed. We  recorded the clinical
and contact data of the patients selected from section C1 and then
phoned them to conduct the interview or alternatively, to set up a
subsequent call. An information sheet and informed consent form
were mailed to the home of all those who agreed to be interviewed,
requiring the prospective interviewees to complete and return both
documents in a postage-paid envelope enclosed for the purpose.
The interviews were recorded in section C2, and the data were then
entered into the database, except for personal identiﬁcation data,
which were disassociated and stored to preserve conﬁdentiality.
All data was collected from February to June 2010.
We performed data analyses for the sample by tumor and, in the
case of colorectal cancer, by sex, as well as a descriptive analysis of
the entire sample. The Chi-square test of independence was  used
to compare tumor type and sex in the categorical variables. The
statistical analyses were performed using the SPSS v15 software
program.
Results
Of the potential sample, a total of 51.2% (583) responded: 52% of
the breast cancer patients; 50.2% of those who  had had colorectal
cancer; and 50% of those treated for prostate cancer (Fig. 1). No
signiﬁcant differences were observed (p > 0.05) between 5-and 10-
year survivors; thus, data were aggregated and analyzed by tumor.
Patients’ sociodemographic and clinical characteristics were
also characterized (Table 1). In terms of clinical aspects, it should
be noted that most of the patients were diagnosed in the early
stages of the disease. Prostate cancer patients presented the most
treatment-related sequelae (53.3%) (p < 0.001), essentially in the
form of sexual impotence and urinary incontinence. The other
most frequent long-term effects, although less common, included
lymphedema in breast cancer patients and permanent stoma in
colorectal cancer patients. Among the patients who did not respond
to the questionnaire, tumor stage at diagnosis and treatment types
were similar to those observed in participants. Non-participants
also experienced the same kinds of adverse effects for each tumor,
though less frequently; this population was  also characterized by
a higher number of patients over 80 for all tumor types respect to
the participants (data not shown).With respect to life changes, most participants had experienced
no relevant variations in their occupational or ﬁnancial status or in
their social relations, though it should be stressed that, of the 14.5%
of women with breast cancer who reported changes in occupational
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Clinical histories
reviewed
n = 3 976 
Exclusions
n = 2 838 
C2 candidates
n = 1 138
Breast: n = 661 
Colorectal: n = 267 
Prostate: n = 210 
Deaths
n = 1 233 
Recurrent or 2nd tumors
n = 792 
Incomplete hospital
treatment
n = 227 
Inclusion criteria
not fulfilled
n = 2 572
Other reasons for
exclusion
n = 266
Excluded due to
impossibility of
completing C2
n = 555   
Patients who
answered C2
n = 583  
Breast: n = 344 
Colorectal: n = 134
Prostate: n =105 
Diagnosis outside
study period
n =  263
Benign tumor
n = 31 
No evidence
of clinical
history
n = 260
Otherreasons
n = 6 
Declined
n = 129 
Age, cognitive
alterations
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Figure 1. Flow chart of enroll
tatus, 30% had lost their jobs as a result of the disease (Table 2). In
erms of lifestyles, the majority had introduced no changes post-
reatment, and among those who had, improved diet and increased
hysical exercise were the most frequent; no signiﬁcant variations
ere observed by tumor type. Insofar as satisfaction with sexual
elations was concerned, prostate cancer patients registered the
ost changes (80%) due to physical alterations and diminished
ibido, whereas in breast and colorectal tumors the chief cause was
 diminished libido (p < 0.001) (Table 2). For all patients, the mean
core for each of the dimensions of the quality of life (SF-36v2, NHP)
y tumor type is presented in Table 3.
Over 80% of patients for each tumor type were undergoing
rug treatment, mainly for arterial hypertension, hypercholes-
erolemia, pain and cardiological problems (Table 4). Breast cancer
atients used tranquilizers and antidepressants more frequently
46%) than their prostate and colorectal cancer counterparts and
ere also more likely (19.8%) to have used complementary thera-
ies (Table 4). Use of these therapies varied throughout time and
isease trajectory, peaking before diagnosis and immediately after
reatment but dropping considerably several years after recovery,
o levels inferior to those observed prior to diagnosis.
Most patients for all tumor types reported follow-up visits,
ainly to the oncologist; visits were more frequent in the case
f breast cancer (p < 0.001) (Table 5). In the previous 12 months,
nly a minority used health care services for oncological consul-
ation or treatment, and those who did need medical attention
elated to cancer generally saw their general practitioner. Other
ealth problems, however, caused close to 70% of sufferers of each
ype of tumor to see their primary care physician (Table 5). Patients
tated that they were satisﬁed or very satisﬁed with the health care
eceived, both oncological and in general (Table 5).
iscussion
Our ﬁndings suggest that long-term breast, colorectal and
rostate cancer survivors who have not experienced recurrence or
ad second neoplasms enjoy a good quality of life. These results
re in line with those reported by other studies13 for this patient
roﬁle. Given the early stages observed at diagnosis, these patients
ad a good prognosis from the outset, also suffering less treatment-
elated morbidity. Nevertheless, one in four patients presented
ome permanent treatment-related sequelae, stemming mainly
rom prostate cancer (sexual impotence and urinary incontinence)
nd, to a lesser extent, from breast cancer (lymphedema). In the
ormer case, it is important to keep in mind that our study sam-Untraceable
n = 302
 C2: telephone questionnaire.
ple was selected on the basis of hospital discharge data, which
include patients who  were surgically treated but not those who
only received brachytherapy or external radiotherapy, a factor
which affects the type of morbidity experienced14,15 and accounts
for the fact that over half of our patients presented sequelae related
to radical prostatectomy.
Most patients in this study were undergoing drug treatment
for comorbidities associated with advanced age, including arte-
rial hypertension, hypercholesterolemia, pain and cardiological
problems. Considering how infrequently patients accessed psy-
chological and psychiatric services, the use of antidepressants and
tranquilizers among women with breast cancer was  quite notable,
a fact which may  indicate underreported psychiatric morbidity
addressed exclusively through pharmacological treatment rather
than with appropriate specialist care. Moreover, despite the fact
that complementary and alternative medicines were seldomly used
by patients in general, their use nevertheless tended to be concen-
trated in breast cancer patients, a common proﬁle reported in the
literature by international studies covering patients from Europe16
and elsewhere17 for women with breast cancer. Usage patterns var-
ied across time that was  lower some years after treatment than it
had been prior to diagnosis; however, this study did not follow
individual patient habits, so we  do not know if the patients were
the same, or if those using complementary therapies after recovery
were doing so for the ﬁrst time. In view of the scant knowledge
about the growing use of such therapies, and taking into account
that their use could reveal some healthcare needs not properly cov-
ered, this is an aspect that warrants greater attention from health
care researchers.
Insofar as use of health care services was concerned, despite
most patients underwent follow-up at the hospital they did visit
the general practitioner for care of cancer-related morbidity. This
ﬁnding is relevant given that it occurred in a context (Spain) which,
despite having a strong primary care system, lacks standardized
models for coordinated follow-up between hospital and primary
care, although some experiences aimed at improving the relation-
ship between primary health and hospital care.18 This is an area
that should clearly be targeted for improvement so as to optimize
and coordinate health care follow-up for all the diseases presented
by these patients.
In view of the marked degree of satisfaction recorded, a possi-
ble explanation for the relatively high use of primary care could
be the level of response to their medical needs (including treat-
ment sequelae) which they encountered. This is in contrast to the
widespread perception, from the hospital perspective, that patient
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Table 1
Sociodemographic proﬁle, diagnosis and treatment.
Colorectal Prostate n (%) Breastn (%)
Men  n (%) Women  n (%) Total n (%) p value tumora p value sexb
Age in years
40–49 y 1 (1.6) 1 (0.7) 25 (7.3) <0.001 0.189
50–59  y 5 (6.9) 8 (12.9) 13 (9.7) 2 (1.9) 92 (26.7)
60–69  y 15 (20.8) 20 (32.3) 35(26.1) 32 (30.5) 122 (35.5)
70–79 y 31 (43.1) 18 (29.0) 49 (36.6) 57 (54.3) 86 (25.0)
>=80  y 14 (13.3) 19 (5.5)
Marital  status
Single 4 (5.6) 1 (1.6) 5 (3.7) 6 (5.7) 20 (5.8) <0.001 0.016
Married/partner 59 (81.9) 40 (64.5) 99 (73.9) 93 (88.6) 242 (70.3)
Widowed 9 (12.5) 19 (30.6) 28 (20.9) 5 (4.8) 59 (17.2)
Separated/divorced 2 (3.2) 2 (1.5) 1 (1.0) 23 (6.7)
Educational level
Incomplete 33 (45.8) 35 (56.5) 68 (50.7) 36 (34.3) 141 (41.0) 0.363 0.189
Primary 20 (27.8) 19 (30.6) 39 (29.1) 38 (36.2) 108 (31.4)
Secondary 13 (18.1) 4 (6.5) 17 (12.7) 19 (18.1) 53 (15.4)
University 4 (5.6) 4 (6.5) 8 (6.0) 11 (10.5) 35 (10.2)
DK/RFc 2 (2.8) 2 (1.5) 1 (1.0) 7 (2.0)
Occupational status
Working 11 (15.3) 4 (6.5) 15 (11.2) 9 (8.6) 76 (22.1) <0.001 <0.001
Unemployed 1 (1.4) 2 (3.2) 3 (2.2) 2 (1.9) 13 (3.8)
Retired 58 (80.6) 32 (51.6) 90 (67.2) 93 (88.6) 135 (39.2)
Homemaker 23 (37.1) 23 (17.2) 103 (29.9)
Incapacity/invalid 2 (2.8) 1 (1.6) 3 (2.2) 1 (1.0) 14 (4.1)
Other  3 (0.9) <0.001 0.276
Tumor  stage at diagnosis
0 - I 16 (22.2) 15 (24.2) 31 (23.1) 19 (18.1) 170 (49.4)
II  30 (41.7) 23 (37.1) 53 (39.6) 32 (30.5) 117 (34.0)
III  - IV 14 (19.4) 19 (30.6) 33 (24.6) 18 (17.1) 27 (7.8)
Unclassiﬁable 12 (16.7) 5 (8.1) 17 (12.7) 36 (34.3) 30 (8.7)
Treatment undergone
Surgery 71 (98.6) 62 (100) 133 (99.3) 98 (93.3) 341 (99.1) 0.002 0.352
Chemotherapy 40 (55.6) 40 (64.5) 80 (59.7) 2 (1.9) 189 (54.9) <0.001 0.380
Radiotherapy 18 (25.0) 13 (21.0) 31 (23.1) 19 (18.1) 250 (72.7) <0.001 0.420
Brachytherapy 1 (1.0) 54 (15.7) <0.001 .
Hormonotherapy 17 (16.2) 206 (59.9) <0.001 .
Adverse effects
No 67 (93.1) 53 (85.5) 120 (89.6) 49 (46.7) 264 (76.7) <0.001 0.153
Yes  5 (6.9) 9 (14.5) 14 (10.4) 56 (53.3) 80 (23.3)
Effects
Permanent stoma 4 (80.0) 2 (22.2) 6 (42.9) <0.001 0.036
Sexual impotence 32 (57.1)
Urinary incontinence 20 (35.7)
Lymphedema 47 (58.8)
Loss  of mobility in upper limbs 12 (15.0)
Early  menopause 8 (10.0)
7.1) 
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Others 1 (20.0) 7 (77.8) 8 (5
Total  (N) 72 62 134
p value tumor: comparison of distributions by tumor; bp value sex: comparison of
istrust would induce rejection of a cancer care follow-up model
n which primary care had a more decisive role 19. Our study data,
nd speciﬁcally the satisfaction expressed by the patients them-
elves, could indicate that patients would not perceive this aspect
s a problem. However more research is needed to conﬁrm these
ndings.
With regard to life changes experienced due to cancer, there
ere remarkably few in the occupational, ﬁnancial, and social rela-
ions spheres; on the contrary, social functioning was  the highest
coring dimension in the quality-of-life questionnaires. In a depar-
ure from other studies20,21, it was notable that in ours, the 12.7%
f all patients had undergone occupational changes, though it is
igniﬁcant that a small number of patients lost their jobs for rea-
ons related to their disease. The few changes observed could
e largely attributable to—and retrospectively associated with—
 work-retirement process linked to patients’ advanced age at1 (1.3)
4 (7.1) 12 (15.0)
105 344
butions by sex; p value: Chi-squared test, cDK/RF: don’t know/refused.
diagnosis. However, the impact of oncological disease on working
life and retirement in Spain requires more qualitative and quanti-
tative research.
Patients reported relevant changes in their sexual relations and,
to a lesser extent, in their lifestyles (only 25% had introduced
healthy changes in diet and exercise). Given the recent evidence
on the beneﬁts of physical activity on risk of recurrence and mor-
tality in breast cancer survivors22 and on the duration and quality
of life in long-term survival23,24, this aspect emerges as a speciﬁc
need requiring intervention targeted to cancer survivors. Sexual-
ity was  also identiﬁed as an area requiring attention, especially
among groups such as prostate cancer patients, among whom
physical alterations are a signiﬁcant component of their disease
and treatment. Indeed, over 30% of all study subjects reported
difﬁculties in this dimension, a result that is in line with other
studies focusing on these tumor types25,26. It is worth noting that,
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Table  2
Life changes.
Colorectal Prostate n (%) Breast n (%)
Men n (%) Women  n (%) Total n (%) p value tumora p value sexb
Occupational status
No change 64 (88.9) 53 (85.5) 117 (87.3) 99 (94.3) 290 (84.3) 0.115 0.523
Changes experienced 8 (11.1) 8 (12.9) 16 (11.9) 5 (4.8) 50 (14.5)
Usual job with modiﬁcations 2 (25.0) 1 (12.5) 3 (18.8) 4 (8.0) 0.339 0.522
Has  changed jobs 1 (12.5) 1 (6.3) 7 (14.0) 0.494 0.302
Loss  of job 1 (12.5) 2 (25.0) 3 (18.8) 1 (20.0) 15 (30.0) 0.635 0.522
Early  retirement 3 (37.5) 2 (25.0) 5 (31.3) 3 (60.0) 9 (18.0) 0.082 0.590
Other  reasons 2 (25.0) 3 (37.5) 5 (31.3) 1 (20.0) 17 (34.0) 0.811 0.590
Financial status
No change 62 (86.1) 56 (90.3) 118 (88.1) 101 (96.2) 297 (86.3) 0.095 0.558
Changes experienced 9 (12.5) 6 (9.7) 15 (11.2) 4 (3.8) 45 (13.1)
Improved 1 (16.7) 1 (6.7) 3 (6.7) 0.867 0.205
Worsened 9 (100) 5 (83.3) 14 (93.3) 4 (100) 42 (93.3)
Social relations
No changes 65 (90.3) 58 (93.5) 123 (91.8) 101 (96.2) 306 (89.0) 0.118 0.108
Changes experienced 7 (9.7) 2 (3.2) 9 (6.7) 4 (3.8) 36 (10.5)
Improved 2 (28.6) 1 (50.0) 3 (33.3) 14 (38.9) 0.299 0.571
Worsened 5 (71.4) 1 (50.0) 6 (66.7) 4 (100) 22 (61.1)
Life  style
No changes 48 (66.7) 39 (62.9) 87 (64.9) 81 (77.1) 258 (75.0) 0.154 0.528
Changes experienced 24 (33.3) 22 (35.5) 46 (34.3) 24 (22.9) 85 (24.7)
Consumes more fruit and vegetables 14 (58.3) 12 (54.5) 26 (56.5) 15 (62.5) 44 (51.8) 0.623 0.796
Follows a diet lower in fats 18 (75.0) 17 (77.3) 35 (76.1) 20 (83.3) 55 (64.7) 0.136 0.857
Avoids overweight 11 (45.8) 7 (31.8) 18 (39.1) 7 (29.2) 25 (29.4) 0.493 0.331
Has  quit smoking 17 (70.8) 9 (40.9) 26 (56.5) 15 (62.5) 35 (41.2) 0.087 0.041
Consumes less alcohol 10 (41.7) 4 (18.2) 14 (30.4) 5 (20.8) 13 (15.3) 0.124 0.084
Exercises regularly or walks 1/2hr/day 17 (70.8) 8 (36.4) 25 (54.3) 15 (62.5) 47 (55.3) 0.787 0.019
Sleeps enough hours to feel well 14 (58.3) 6 (27.3) 20 (43.5) 14 (58.3) 30 (35.3) 0.121 0.034
In  general, avoids health risks 13 (54.2) 5 (22.7) 18 (39.1) 6 (25.0) 22 (25.9) 0.246 0.029
Follows medical advice given by doctors 14 (58.3) 8 (36.4) 22 (47.8) 15 (62.5) 29 (34.1) 0.032 0.136
Others 1 (4.2) 2 (9.1) 3 (6.5) 4 (4.7) 0.456 0.499
Satisfaction in sexual relations
No changes 27 (37.5) 15 (24.2) 42 (31.3) 18 (17.1) 180 (52.3) <0.001 0.006
Changes experienced 28 (38.9) 16 (25.8) 44 (32.8) 85 (81.0) 98 (28.5)
Diminished libido 13 (46.4) 10 (62.5) 23 (52.3) 7 (8.2) 48 (49.0) <0.001 0.305
Physical alterations 10 (35.7) 3 (18.8) 13 (29.5) 66 (77.6) 28 (28.6) <0.001 0.235
Other  reasons 9 (32.1) 5 (31.3) 14 (31.8) 14 (16.5) 40 (40.8) 0.002 0.951
Refused to answer 17 (23.6) 31 (50.0) 48 (35.8) 2 (1.9) 66 (19.2)
Total  (N) 72 62 134 105 344
a p value tumor: comparison of distributions by tumor.
b p value sex: comparison of distributions by sex; p value: Chi-squared test.
Table 3
Quality of life.
Colorectal
Men  Mean (SD)a Women  Mean (SD) Total Mean (SD) Prostate Mean (SD) Breast Mean (SD)
SF-36 questionnaire
Physical function 78.2 (25.1) 66.1 (28.7) 72.8 (27.4) 82.4 (20.2) 71.9 (25.6)
Role-physical 90.1 (27.2) 85.8 (32.8) 88.2 (29.8) 94.3 (19.7) 80.8 (35.7)
Bodily pain 85.3 (22.1) 75.7 (21.6) 81.0 (22.3) 85.1 (19.1) 74.0 (24.2)
General health 65.8 (21.0) 57.6 (21.2) 62.1 (21.4) 68.7 (17.5) 61.3 (22.4)
Vitality 68.2 (23.8) 60.2 (23.6) 64.6 (24.0) 71.7 (20.5) 61.0 (23.0)
Social function 92.4 (16.0) 88.6 (17.3) 90.7 (16.6) 90.4 (19.2) 86.8 (19.8)
Role-emotional 95.3 (20.5) 91.4 (23.0) 93.5 (21.7) 96.2 (16.3) 87.1 (31.3)
Mental health 76.8 (16.7) 66.6 (21.2) 72.2 (19.5) 78.5 (16.5) 68.9 (20.3)
Physical component 49.1 (7.9) 45.8 (9.6) 47.6 (8.8) 50.3 (7.4) 46.6 (9.7)
Mental component 52.5 (6.9) 49.9 (9.1) 51.3 (8.0) 52.6 (7.4) 49.3 (9.9)
Nottingham Health Proﬁle
Physical mobility 17.5 (23.8) 25.7 (26.9) 21.3 (25.5) 13.0 (19.8) 20.6 (24.2)
Pain  16.2 (26.4) 25.7 (33.6) 20.5 (30.2) 11.9 (24.4) 21.9 (28.3)
Sleep  24.9 (30.2) 28.7 (31.4) 26.7 (30.7) 22.2 (27.7) 27.3 (32.4)
Energy 18.5 (32.8) 24.2 (32.4) 21.1 (32.6) 10.6 (26.2) 24.2 (35.8)
Social isolation 4.6 (11.6) 8.0 (17.9) 6.2 (14.8) 4.2 (12.1) 8.6 (17.8)
Emotional reactions 10.3 (18.0) 19.8 (27.2) 14.6 (23.1) 8.0 (13.8) 17.6 (22.3)
Total  (N) 72 62 134 105 344
a(SD): standard deviation.
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Table 4
Drug treatment and complementary therapies.
Colorectal
Men  Women  Total Prostate Breast p value tumora p value sexb
n (%) n (%) n (%) n (%) n (%)
Drug treatment
Undergoing drug treatment
No 14 (19.4) 10 (16.1) 24 (17.9) 13 (12.4) 67 (19.5) 0.478 0.618
Yes  58 (80.6) 52 (83.9) 110 (82.1) 92 (87.6) 276 (80.2)
Reason
Cancer 9 (3.3) 0.194 0.509
Other  causes 56 (96.6) 50 (96.2) 106 (96.4) 85 (92.4) 254 (92.0)
Both  1 (1.7) 2 (3.8) 3 (2.7) 6 (6.5) 11 (4.0)
DK/RFc 1 (1.7) 1 (0.9) 1 (1.1) 2 (0.7)
Type  of current medication
Painkillers/anti-inﬂammatories 19 (32.8) 27 (51.9) 46 (41.8) 23 (25.0) 134 (48.6)
Tranquilizers/sedatives 6 (10.3) 8 (15.4) 14 (12.7) 7 (7.6) 63 (22.8)
Antidepressants 3 (5.2) 7 (13.5) 10 (9.1) 4 (4.3) 64 (23.2)
Antibiotics 4 (6.9) 3 (5.8) 7 (6.4) 1 (1.1) 11 (4.0)
For  the heart 17 (29.3) 7 (13.5) 24 (21.8) 28 (30.4) 39 (14.1)
For  arterial tension 34 (58.6) 23 (44.2) 57 (51.8) 53 (57.6) 124 (44.9)
For  cholesterol 21 (36.2) 22 (42.3) 43 (39.1) 35 (38.0) 78 (28.3)
Insulin or for diabetes 13 (22.4) 13 (25.0) 26 (23.6) 15 (16.3) 34 (12.3)
For  the stomach 6 (10.3) 16 (30.8) 22 (20.0) 20 (21.7) 58 (21.0)
For  asthma/allergies/
cough/skin/eyes
10 (17.2) 10 (19.2) 20 (18.2) 11 (12.0) 57 (20.7)
Weight loss/sleeping/
vitamins/laxatives
14 (24.1) 20 (38.5) 34 (30.9) 30 (32.6) 169 (61.2)
Hormonal Replacement Therapy
(women)
11 (19.0) 11 (10.0) 15 (5.4)
Contraceptives (women) 11 (19.0) 11 (10.0) 1 (0.4)
Others 18 (31.0) 14 (26.9) 32 (29.1) 38 (41.3) 103 (37.3)
Complementary therapies
Used them at some time in their lives
No 68 (94.4) 52 (83.9) 120 (89.6) 97 (92.4) 273 (79.4) 0.003 0.093
Yes  4 (5.6) 8 (12.9) 12 (9.0) 8 (7.6) 68 (19.8)
Time  of use
Before cancer diagnosis 3 (75.0) 8 (100) 11 (91.7) 6 (75.0) 40 (58.8) 0.073 0.140
During cancer treatment 4 (50.0) 4 (33.3) 3 (37.5) 33 (48.5) 0.556 0.083
After  completion of treatment 2 (50.0) 2 (25.0) 4 (33.3) 5 (62.5) 40 (58.8) 0.240 0.386
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p value tumor: comparison of distributions by tumor; bp value sex: comparison of
n general, this is not an area covered by the Spanish healthcare
ystem. These spheres could possibly beneﬁt from an educa-
ional and support intervention based on fully integrated nursing
are.27
In any case, it is worth underlining the overall high quality of
ife reported by these patients in comparison to the general Spanish
opulation aged 60 years or older. Indeed, the quality-of-life scores
f the survivors in our study exceeded the values in all dimensions28
s well as in the mental component of the SF-36 scale, while physi-
al wellbeing was  similar between the two groups.29 The prevalent
erception among study subjects of having a better quality of life
ould stem from the experience of surviving cancer. This aspect
s worth exploring in greater depth at a qualitative level in future
esearch.
The results of this study should be assessed in light of certain
imitations. Firstly, we used health-related quality-of-life question-
aires in the telephone interview, a methodology that has given
ise to conﬂicting evidence as to whether it is equivalent to self
dministration30 or if it favors a participant proﬁle with slight phys-
cal and mental advantages in comparison to those who complete
uestionnaires in writing.31 Moreover, some candidates did not
articipate for reasons of advanced age and/or cognitive alterations.
aken together, these two factors amount to a study limitation.
urthermore, there is no way of knowing if there were clinical or
ocial differences between the patients who could not be located
or administrative reasons and those who declined to participate(50.0) 3 (37.5) 23 (33.8) 0.560 0.221
105 344
butions by sex; p value: Chi-squared test, cDK/RF: don’t know/refused.
in the study. Finally, the data on adverse effects were obtained by
examining clinical histories, a fact which may  have led to a slight
underestimation of these consequences. Also, the higher propor-
tion of aged non-participants could be explained by the fact that
they are dead and we cannot know it.
In conclusion, this study provides a proﬁle of long-term breast,
prostate, and colorectal cancer survivors who were diagnosed at
an early stage, experienced neither recurrence nor second neo-
plasms, presented cancer-related morbidity of a low level and
of little complexity, and had a good quality of life. For the most
part, they reported using primary care services mainly for care of
other chronic diseases, as well as for opportunistic treatment
of cancer-related sequelae, despite the fact that ongoing onco-
logical follow-up was centralized at a hospital level. The patients
stated that they were satisﬁed with the care received at all health
care levels. Emotional needs, sexuality, and healthy lifestyles were
identiﬁed as speciﬁc areas in need of potential care or intervention.
The results of the current study suggest that long-term cancer
survivors treated in our health care system could beneﬁt from a
comprehensive follow-up approach focusing on health promotion
and chronic disease and as well as on surveillance of recurrence and
long-term side effects. Therefore, our efforts could be addressed
to explore a follow-up model for cancer survivors in which pri-
mary care would have an outstanding and integrated role. Further
research should be developed so as to conﬁrm our ﬁndings and to
assess new follow-up care models.
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Table  5
Use and Satisfaction of health care services.
Colorectal
Men n (%) Women n (%) Total n (%) Prostate n (%) Breast n (%) p value tumora p value sexb
USE of health care services
Cancer  follow-up visits
Performance of cancer-related visits
No  25  (34.7)  17  (27.4) 42 (31.3) 6 (5.7) 56 (16.3)  <0.001 0.407
Yes  46  (63.9)  45  (72.6) 91 (67.9) 99 (94.3) 288 (83.7)
Specialists  seen
Oncologist 35  (76.1)  28  (62.2) 63 (69.2) 44 (44.4) 260 (90.3) <0.001 0.152
Surgeon  11  (23.9) 15 (33.3) 26 (28.6) 31 (31.3) 23 (8.0) <0.001 0.320
Radiotherapist  5 (10.9) 1 (2.2) 6 (6.6) 3 (3.0) 39 (13.5)  0.005 0.097
Others  4 (8.7) 8 (17.8) 12 (13.2) 38 (38.4) 48 (16.7)  <0.001 0.200
Cancer-related  morbidity  visits
Needs health care
No 57  (79.2)  53  (85.5) 110 (82.1) 90 (85.7) 279 (81.1) 0.186 0.342
Yes  15  (20.8) 9 (14.5) 24 (17.9) 14 (13.3) 65 (18.9)
Professionals  visited in
preceding 12  months
Specialist 2 (13.3)  2 (8.3) 15 (23.1)  0.051 0.253
General  practitioner 10 (66.7)  5 (55.6) 15 (62.5) 7 (50.0) 25 (38.5)  0.122 0.586
Support  carec 2 (13.3)  4 (44.4) 6 (25.0) 2 (14.3) 22 (33.8)  0.302 0.088
Others  3 (33.3) 3 (12.5) 5 (35.7) 18 (27.7)  0.214 0.017
Non-cancer-related  morbidity visits
Needs health care
No 27  (37.5)  16  (25.8) 43 (32.1) 30 (28.6) 97 (28.2)  0.844 0.148
Yes  45  (62.5)  46  (74.2) 91 (67.9) 75 (71.4) 246 (71.5)
Professionals  visited in
preceding 12  months
Specialist 6 (13.3)  6 (13.0) 12 (13.2) 14 (18.7) 45 (18.3)  0.510 0.967
General  practitioner 28  (62.2)  39  (84.8) 67 (73.6) 54 (72.0) 179 (72.8)  0.973 0.015
Support  carec 6 (13.3)  17  (37.0) 23 (25.3) 15 (20.0) 56 (22.8)  0.722 0.010
Others  11  (24.4)  14  (30.4) 25 (27.5) 14 (18.7) 69 (28.0) 0.258 0.522
SATISFACTION  of health care services
Related  to cancer 0.248 0.404
Dissatisﬁed  1 (1.4) 2 (3.2) 3 (2.2) 1 (1.0) 6 (1.7)
Indifferent  1 (1.6) 1 (0.7) 2 (1.9) 4 (1.2)
Satisﬁed  14  (19.4)  16  (25.8) 30 (22.4) 33 (31.4) 70 (20.3)
Very  satisﬁed 57  (79.2)  42  (67.7) 99 (73.9) 69 (65.7) 264 (76.7)
DK/RFd 1 (1.6) 1 (0.7)
In  general  0.207 0.059
Dissatisﬁed  1 (1.6) 1 (0.7) 3 (2.9) 7 (2.0)
Indifferent  2 (2.8) 3 (4.8) 5 (3.7) 3 (2.9) 9 (2.6)
Satisﬁed  27  (37.5)  18  (29.0) 45 (33.6) 33 (31.4) 111 (32.3)
Very  satisﬁed 43  (59.7)  38  (61.3) 81 (60.4) 66 (62.9) 217 (63.1)
DK/RFd 2 (3.2) 2 (1.5)
Total  (N)  72  62 134 105 344
a stribu
a
p value tumor: comparison of distributions by tumor; bp value sex: comparison of di
nd  Nurse; dDK/RF: don’t know/refused.
What is known about subject?
The long-term cancer survivorship is under focus of
research given the growing number of survivors and the lack
of knowledge on their health care needs. Most of literature is
based on Anglo-Saxon experiences. This paper explores the
health status of survivors and the use of healthcare resources
in relation to the Spanish healthcare system.
What does this study add to the literature?
This study gives information on breast, prostate and colo-
rectal cancer survivor’s health status and the use of resources
within our healthcare system. This allowed for identifying a
survivor proﬁle in accordance to quality of life and sequelae
issues. This proﬁle could take advantage of a model of follow-
up in which primary care would play a relevant role.tions by sex; p value: Chi-squared test; cSupport care: Psychologist, Physiotherapist,
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